Literature DB >> 27347068

Granulocyte colony-stimulating factor inhibits CXCR4/SDF-1α signaling and overcomes stromal-mediated drug resistance in the HL-60 cell line.

Xianfu Sheng1, Hua Zhong1, Haixia Wan1, Jihua Zhong1, Fangyuan Chen1.   

Abstract

Combining cytarabine, aclarubicin and granulocyte colony-stimulating factor (G-CSF) has demonstrated marked efficacy in the treatment of elderly and relapsed/refractory patients with acute myeloid leukemia (AML); however, the role of G-CSF remains poorly understood. The present study aimed to investigate the ability of G-CSF to overcome stromal-mediated drug resistance and the underlying molecular mechanism. Two types of co-culture models were established in the HS-5 human bone marrow/stromal and HL-60 human promyelocytic leukemia cell lines, in order to imitate the interactions between stromal and leukemia cells in vitro, which is mediated by the stromal cell-derived factor (SDF)-1α signaling axis. In the present study, HL-60 cells were attracted and adhered to HS-5 cells using migration assay and flow cytometry, respectively; however, these interactions were inhibited by treatment with G-CSF and/or the C-X-C chemokine receptor type 4 (CXCR4) antagonist, AMD3100. Co-culture with HS-5 cells, including direct and indirect contact, protected HL-60 cells against spontaneous apoptosis or drug-induced apoptosis; however, these protective effects were disrupted by treatment with G-CSF and/or AMD3100. Notably, G-CSF and/or AMD3100 did not alter cell viability or apoptosis when HL-60 cells were cultured with medium alone. In addition, G-CSF significantly reduced the expression levels of surface CXCR4 protein, total CXCR4 protein and CXCR4 mRNA, and significantly upregulated the expression of microRNA (miR)-146a. Conversely, AMD3100 significantly reduced surface CXCR4 expression levels, but not the total CXCR4, CXCR4 mRNA or miR-146a expression levels. The results of the present study suggested that interfering with the CXCR4/SDF-1α signaling axis via G-CSF inhibited the migration and adhesion of HL-60 cells to HS-5 cells and eliminated HS5 cell-mediated protective effects. Furthermore, G-CSF administration reduced CXCR4 expression levels by upregulating the expression of miR-146a, whereas AMD3100 appeared to be predominantly dependent on receptor internalization. Therefore, a G-CSF/miR-146a/CXCR4 pathway may explain how G-CSF inhibits CXCR4/SDF-1α signaling and overcomes stromal cell-mediated drug resistance in acute myeloid leukemia.

Entities:  

Keywords:  AMD3100; C-X-C chemokine receptor type 4/stromal cell-derived factor-1α axis; drug resistance; granulocyte colony-stimulating factor; microRNA-146a

Year:  2016        PMID: 27347068      PMCID: PMC4906714          DOI: 10.3892/etm.2016.3268

Source DB:  PubMed          Journal:  Exp Ther Med        ISSN: 1792-0981            Impact factor:   2.447


  38 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

Review 2.  MicroRNAs: small RNAs with a big role in gene regulation.

Authors:  Lin He; Gregory J Hannon
Journal:  Nat Rev Genet       Date:  2004-07       Impact factor: 53.242

Review 3.  Regulation of CXCR4 signaling.

Authors:  John M Busillo; Jeffrey L Benovic
Journal:  Biochim Biophys Acta       Date:  2006-11-10

4.  Plerixafor (AMD3100) and granulocyte colony-stimulating factor (G-CSF) mobilize different CD34+ cell populations based on global gene and microRNA expression signatures.

Authors:  Robert E Donahue; Ping Jin; Aylin C Bonifacino; Mark E Metzger; Jiaqiang Ren; Ena Wang; David F Stroncek
Journal:  Blood       Date:  2009-07-14       Impact factor: 22.113

5.  AMD3100 disrupts the cross-talk between chronic lymphocytic leukemia cells and a mesenchymal stromal or nurse-like cell-based microenvironment: pre-clinical evidence for its association with chronic lymphocytic leukemia treatments.

Authors:  Basile Stamatopoulos; Nathalie Meuleman; Cécile De Bruyn; Karlien Pieters; Philippe Mineur; Christine Le Roy; Stéphane Saint-Georges; Nadine Varin-Blank; Florence Cymbalista; Dominique Bron; Laurence Lagneaux
Journal:  Haematologica       Date:  2011-11-04       Impact factor: 9.941

6.  G-CSF down-regulation of CXCR4 expression identified as a mechanism for mobilization of myeloid cells.

Authors:  Hyun Kyung Kim; Maria De La Luz Sierra; Cassin Kimmel Williams; A Virginia Gulino; Giovanna Tosato
Journal:  Blood       Date:  2006-03-14       Impact factor: 22.113

Review 7.  Novel agents and regimens for acute myeloid leukemia: 2009 ASH annual meeting highlights.

Authors:  Xiongpeng Zhu; Yuehua Ma; Delong Liu
Journal:  J Hematol Oncol       Date:  2010-04-23       Impact factor: 17.388

8.  Down-regulation of CXCR4 by inducible small interfering RNA inhibits breast cancer cell invasion in vitro.

Authors:  Yangchao Chen; George Stamatoyannopoulos; Chao-Zhong Song
Journal:  Cancer Res       Date:  2003-08-15       Impact factor: 12.701

9.  MicroRNA-146a and AMD3100, two ways to control CXCR4 expression in acute myeloid leukemias.

Authors:  I Spinello; M T Quaranta; R Riccioni; V Riti; L Pasquini; A Boe; E Pelosi; A Vitale; R Foà; U Testa; C Labbaye
Journal:  Blood Cancer J       Date:  2011-06-24       Impact factor: 11.037

Review 10.  A meta-analysis of CAG (cytarabine, aclarubicin, G-CSF) regimen for the treatment of 1029 patients with acute myeloid leukemia and myelodysplastic syndrome.

Authors:  Guoqing Wei; Wanmao Ni; Jen-wei Chiao; Zhen Cai; He Huang; Delong Liu
Journal:  J Hematol Oncol       Date:  2011-11-14       Impact factor: 17.388

View more
  1 in total

1.  Combination regimen of granulocyte colony-stimulating factor and recombinant human thrombopoietin improves the curative effect on elderly patients with leukemia through inducing pyroptosis and ferroptosis of leukemia cells.

Authors:  Xiaobin Wang; Xiaoyu Liu; Huihan Wang
Journal:  Cancer Gene Ther       Date:  2022-06-29       Impact factor: 5.987

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.